AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read

ArriVent BioPharma, Inc. Stock 12‑Month Price Target Cut to $37.55, Implies 32% Upside

ArriVent BioPharma's average price target was reduced by analysts from $42.45 to $37.55, with a range of $18 to $50. This suggests a 32% upside from the Oct. 5 closing price. All 12 analysts maintain a 'Buy' rating.

Original reporting
tradingview.com
Published Oct 6, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ArriVent BioPharma, Inc. Stock 12‑Month Price Target Cut to $37.55, Implies 32% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The price‑target reduction signals analysts' lowered expectations, which may prompt short‑term selling.

02

Market read

Analyst target cuts are a modest catalyst; limited trading relevance unless accompanied by new data.

03

What to watch

Potential upcoming clinical trial results not reflected in current analyst estimates.

Relevance 5/10Novelty 4/10Timing: post-market today

Background

ArriVent BioPharma is a clinical-stage biotech focused on rare diseases.

Market effects

Sector

May slightly dampen sentiment in the biotech sector.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Target cut could be an overreaction; upside still possible if upcoming data beats expectations.

Key entities

  • Company
    ArriVent BioPharma, Inc.

    Subject of the price‑target update.

Read at source← All news

Related articles

OCT 6
HighAI 9/10

ArriVent collapses on disappointing lung cancer data

ArriVent BioPharma's lung cancer drug, furmonertinib, failed to meet its main goal in a late-stage study, missing a key benchmark in tumor progression. The company's shares fell over 50% in pre-market trading. CEO Bing Yao stated the company will review the data to determine next steps. The drug is approved in China for certain lung cancers, but the study's failure may limit its market potential.

finance.yahoo.com2 min
OCT 6
$AVBPHighAI 8/10

Why is Arrivent Biopharma stock collapsing today?

Arrivent Biopharma (AVBP) shares dropped 56.7% in pre-market trading after its Phase 3 FURVENT trial failed to meet the primary endpoint of progression-free survival for firmonertinib. The 240mg dose showed a median PFS of 11.0 months vs. 9.5 months for chemotherapy, but the hazard ratio was not statistically significant. CEO Bing Yao noted the disappointing results and the company is evaluating next steps.

investing.com1 min
OCT 6
$AVBPHighAI 8/10

ArriVent stock tumbles 60% after trial misses primary endpoint

ArriVent BioPharma's (AVBP) stock dropped 63% after its Phase 3 FURVENT trial for firmonertinib failed to meet the primary endpoint of progression-free survival in NSCLC patients. The trial compared two doses of firmonertinib against chemotherapy, with neither dose achieving statistical significance. Secondary endpoints showed some clinical benefit, but the company expressed disappointment in the results. The trial enrolled 398 patients globally.

investing.com2 min
OCT 6
$AVBPHighAI 9/10

ArriVent: Phase 3 FURVENT misses primary PFS endpoint by BICR; signals on secondary endpoints

ArriVent's Phase 3 FURVENT trial of firmonertinib missed the primary PFS endpoint by BICR (p=0.0654). The 240mg arm showed median PFS of 11.0 months vs. 9.5 months for control. Investigator-assessed PFS favored 240mg (11.1 vs. 7.1 months). Confirmed ORR by BICR was 60% for 240mg, 35% for 160mg, and 33% for control. Safety data were consistent with prior studies.

tradingview.com2 min
OCT 6
$AVBPMedAI 9/10

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC NEWTOWN SQUARE, PA, October 6, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage

SEC EDGAR 8-K2 min